CR20220560A - Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso - Google Patents
Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de usoInfo
- Publication number
- CR20220560A CR20220560A CR20220560A CR20220560A CR20220560A CR 20220560 A CR20220560 A CR 20220560A CR 20220560 A CR20220560 A CR 20220560A CR 20220560 A CR20220560 A CR 20220560A CR 20220560 A CR20220560 A CR 20220560A
- Authority
- CR
- Costa Rica
- Prior art keywords
- myeloid cells
- receptor expressed
- agonists
- methods
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripción proporciona compuestos de la Fórmula I, útiles para la activación del receptor de activación expresado en células mieloides 2 (“TREM2”). I La presente descripción también proporciona composiciones farmacéuticas que comprenden los compuestos, usos de los compuestos, y composiciones para el tratamiento, por ejemplo, de un trastorno neurodegenerativo. Además, la descripción proporciona productos intermedios útiles en la síntesis de compuestos de la Fórmula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063019772P | 2020-05-04 | 2020-05-04 | |
PCT/US2021/070507 WO2021226629A1 (en) | 2020-05-04 | 2021-05-04 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220560A true CR20220560A (es) | 2023-08-18 |
Family
ID=78468522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220560A CR20220560A (es) | 2020-05-04 | 2021-05-04 | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso |
Country Status (19)
Country | Link |
---|---|
US (4) | US11608344B2 (es) |
EP (1) | EP4146222A1 (es) |
JP (1) | JP2023525035A (es) |
KR (1) | KR20230019822A (es) |
CN (1) | CN115867284A (es) |
AR (1) | AR122010A1 (es) |
AU (1) | AU2021266805A1 (es) |
BR (1) | BR112022022341A2 (es) |
CA (1) | CA3182105A1 (es) |
CL (1) | CL2022003047A1 (es) |
CO (1) | CO2022015930A2 (es) |
CR (1) | CR20220560A (es) |
CU (1) | CU20220064A7 (es) |
EC (1) | ECSP22089527A (es) |
IL (1) | IL297833A (es) |
MX (1) | MX2022013842A (es) |
PE (1) | PE20230846A1 (es) |
TW (1) | TW202208355A (es) |
WO (1) | WO2021226629A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
IL297845A (en) | 2020-05-04 | 2023-01-01 | Amgen Inc | Heterocyclic compounds as a stimulating receptor expressed in myeloid cells 2 agonists and methods of use |
JP2023552553A (ja) * | 2020-12-04 | 2023-12-18 | ビジル・ニューロサイエンス・インコーポレイテッド | Trem2アゴニストを使用した、atp結合カセットトランスポーター1機能不全に関連する疾患の治療 |
AU2022269034A1 (en) * | 2021-05-04 | 2023-11-16 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
WO2023192288A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2940972A (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
US2963481A (en) | 1959-11-27 | 1960-12-06 | Smith Kline French Lab | 6-pteridinecarboxylic acid esters |
JPH09510695A (ja) | 1994-01-03 | 1997-10-28 | エイシア・ファーマシュウティカルズ,インコーポレイテッド | 8−アザ、6−アザ、および6,8−ジアザ−1,4−ジヒドロキノキサリン−2,3−ジオン類およびそのグリシン/nmdaリセプターに対するアンタゴニストとしての使用 |
AU9503998A (en) | 1997-10-28 | 1999-05-17 | Warner-Lambert Company | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents |
CA2431904A1 (en) | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
JP2003005355A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はx線用ネガ型レジスト組成物 |
WO2005007099A2 (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents |
PT1673092E (pt) | 2003-10-17 | 2007-11-23 | 4 Aza Ip Nv | ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia'' |
BRPI0415683A (pt) * | 2003-11-03 | 2006-12-19 | Warner Lambert Co | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central |
DK1737831T3 (da) | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
KR100659088B1 (ko) | 2005-07-15 | 2006-12-21 | 삼성에스디아이 주식회사 | 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자 |
US20080261974A1 (en) | 2005-09-23 | 2008-10-23 | Kevin J Duffy | Novel Chemical Compounds |
EP1996191A4 (en) | 2006-03-02 | 2010-05-19 | Glaxosmithkline Llc | THIAZOLONE AS A PI3 KINASE INHIBITOR |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
US20090318456A1 (en) | 2006-07-06 | 2009-12-24 | Gilead Sciences, Inc. | Substituted pteridines for the treatment and prevention of viral infections |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
KR101438245B1 (ko) | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Mtor 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
AU2008241483B2 (en) | 2007-04-18 | 2011-03-24 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
BRPI0818426A2 (pt) | 2007-10-15 | 2017-06-13 | Astrazeneca Ab | produto de combinação, uso de um produto de combinação, e, método para tratar câncer |
EP2244709A4 (en) | 2008-02-07 | 2012-02-29 | Synta Pharmaceuticals Corp | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS |
US8298825B1 (en) | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
DK2356109T3 (en) | 2008-10-10 | 2017-03-13 | Vm Discovery Inc | COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES |
AU2010226826A1 (en) | 2009-03-18 | 2011-10-13 | Merck Sharp & Dohme Corp. | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
WO2011014039A1 (en) | 2009-07-31 | 2011-02-03 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
US20110124597A1 (en) | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
JP2013522249A (ja) * | 2010-03-16 | 2013-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | モルホリニルキナゾリン |
US9139592B2 (en) | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
KR101497124B1 (ko) | 2011-11-28 | 2015-03-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치 |
MX357296B (es) | 2012-02-08 | 2018-07-03 | Janssen Sciences Ireland Uc | Derivados piperidinopirimidinicos para el tratamiento de infecciones viricas. |
CN103374021B (zh) | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
WO2014146249A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors |
JP6192836B2 (ja) | 2013-07-30 | 2017-09-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Rorcモジュレーターとしてのアザインドール化合物 |
CN105814022B (zh) | 2013-12-09 | 2018-09-28 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合的二环杂芳族衍生物 |
KR20150080966A (ko) | 2014-01-02 | 2015-07-13 | 최돈수 | 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료 |
KR20160060572A (ko) | 2014-11-19 | 2016-05-30 | 주식회사 엠비케이 | 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기 |
US10403826B2 (en) | 2015-05-07 | 2019-09-03 | Universal Display Corporation | Organic electroluminescent materials and devices |
JP6805235B2 (ja) | 2015-08-11 | 2020-12-23 | メルク パテント ゲーエムベーハー | 有機エレクトロルミネッセンス素子のための材料 |
WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
US10573692B2 (en) | 2016-04-06 | 2020-02-25 | Samsung Display Co., Ltd. | Organic light-emitting device having a sealing thin film encapsulation portion |
KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
LT3442947T (lt) | 2016-04-15 | 2023-09-11 | Epizyme, Inc. | Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai |
CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
WO2018066812A1 (en) | 2016-10-05 | 2018-04-12 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent compound and organic electroluminescent device comprising the same |
WO2018108110A1 (zh) | 2016-12-13 | 2018-06-21 | 广州华睿光电材料有限公司 | 金属有机配合物及其应用、混合物、有机电子器件 |
TW201843143A (zh) | 2017-03-13 | 2018-12-16 | 德商麥克專利有限公司 | 含有芳基胺結構之化合物 |
WO2018169352A1 (en) | 2017-03-16 | 2018-09-20 | Rohm And Haas Electronic Materials Korea Ltd. | Organic electroluminescent device |
KR102335935B1 (ko) | 2017-03-22 | 2021-12-06 | 덕산네오룩스 주식회사 | 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
US20200113901A1 (en) | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
KR102389204B1 (ko) | 2017-04-18 | 2022-04-21 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
US11672800B2 (en) | 2017-04-21 | 2023-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
WO2018204765A1 (en) | 2017-05-05 | 2018-11-08 | Pairnomix, Llc | Methods of treating epilepsy and kcnq2 related conditions |
JP2020523389A (ja) | 2017-06-13 | 2020-08-06 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 抗ウイルス薬 |
EP3689866A4 (en) | 2017-09-26 | 2021-07-07 | Nippon Soda Co., Ltd. | QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE |
CN111343989A (zh) | 2017-10-18 | 2020-06-26 | Epizyme股份有限公司 | 使用ehmt2抑制剂用于免疫疗法的方法 |
CA3081946A1 (en) | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in preventing or treating blood disorders |
CN108484680B (zh) | 2018-01-31 | 2020-12-11 | 马鞍山南京大学高新技术研究院 | 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物 |
MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
US20200075870A1 (en) | 2018-08-22 | 2020-03-05 | Universal Display Corporation | Organic electroluminescent materials and devices |
CN109265457A (zh) | 2018-11-01 | 2019-01-25 | 中国药科大学 | 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法 |
WO2020231739A2 (en) | 2019-05-10 | 2020-11-19 | Antidote Ip Holdings, Llc | Compounds and methods for treating cancer |
CN110283171A (zh) | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用 |
US11820783B2 (en) | 2019-09-06 | 2023-11-21 | Universal Display Corporation | Organic electroluminescent materials and devices |
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
CN111454265B (zh) | 2020-05-07 | 2021-08-24 | 宁波卢米蓝新材料有限公司 | 一种稠杂环化合物及其制备方法和应用 |
-
2021
- 2021-05-03 TW TW110115924A patent/TW202208355A/zh unknown
- 2021-05-04 PE PE2022002567A patent/PE20230846A1/es unknown
- 2021-05-04 KR KR1020227038841A patent/KR20230019822A/ko active Search and Examination
- 2021-05-04 US US17/302,502 patent/US11608344B2/en active Active
- 2021-05-04 IL IL297833A patent/IL297833A/en unknown
- 2021-05-04 WO PCT/US2021/070507 patent/WO2021226629A1/en active Application Filing
- 2021-05-04 MX MX2022013842A patent/MX2022013842A/es unknown
- 2021-05-04 BR BR112022022341A patent/BR112022022341A2/pt unknown
- 2021-05-04 AR ARP210101218A patent/AR122010A1/es unknown
- 2021-05-04 AU AU2021266805A patent/AU2021266805A1/en active Pending
- 2021-05-04 EP EP21800538.7A patent/EP4146222A1/en active Pending
- 2021-05-04 CU CU2022000064A patent/CU20220064A7/es unknown
- 2021-05-04 CA CA3182105A patent/CA3182105A1/en active Pending
- 2021-05-04 CN CN202180047705.7A patent/CN115867284A/zh active Pending
- 2021-05-04 JP JP2022567487A patent/JP2023525035A/ja active Pending
- 2021-05-04 CR CR20220560A patent/CR20220560A/es unknown
-
2022
- 2022-11-03 CL CL2022003047A patent/CL2022003047A1/es unknown
- 2022-11-04 CO CONC2022/0015930A patent/CO2022015930A2/es unknown
- 2022-11-21 EC ECSENADI202289527A patent/ECSP22089527A/es unknown
- 2022-11-30 US US18/072,501 patent/US11884675B2/en active Active
- 2022-11-30 US US18/072,505 patent/US11912711B2/en active Active
-
2023
- 2023-09-21 US US18/472,147 patent/US20240182477A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023525035A (ja) | 2023-06-14 |
MX2022013842A (es) | 2023-02-22 |
US11912711B2 (en) | 2024-02-27 |
US20230295170A1 (en) | 2023-09-21 |
ECSP22089527A (es) | 2023-02-28 |
AU2021266805A1 (en) | 2022-12-01 |
IL297833A (en) | 2023-01-01 |
TW202208355A (zh) | 2022-03-01 |
CO2022015930A2 (es) | 2023-01-26 |
US20230295169A1 (en) | 2023-09-21 |
CN115867284A (zh) | 2023-03-28 |
EP4146222A1 (en) | 2023-03-15 |
US11608344B2 (en) | 2023-03-21 |
WO2021226629A1 (en) | 2021-11-11 |
BR112022022341A2 (pt) | 2023-01-10 |
US20240182477A1 (en) | 2024-06-06 |
PE20230846A1 (es) | 2023-05-23 |
CL2022003047A1 (es) | 2023-07-14 |
AR122010A1 (es) | 2022-08-03 |
KR20230019822A (ko) | 2023-02-09 |
US20230002390A1 (en) | 2023-01-05 |
CU20220064A7 (es) | 2023-06-13 |
CA3182105A1 (en) | 2021-11-11 |
US11884675B2 (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220560A (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso | |
CR20220559A (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso | |
US11052070B2 (en) | Riluzole prodrugs and their use | |
IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
UA85576C2 (ru) | Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата | |
CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
MX2007008614A (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r). | |
TW200732313A (en) | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | |
PL1725536T3 (pl) | Pochodne imidazoliny mające czynność CB1-antagonistyczną | |
TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
MEP6808A (xx) | Priperidinoilpirodolini agonisti receptora menalokortina tipa 4 | |
GB0517175D0 (en) | Compounds | |
MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
MX2008002805A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico. | |
MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
GB0701366D0 (en) | Novel pharmaceutical compositions | |
TW200740781A (en) | Novel compounds | |
MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
MY138547A (en) | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | |
TW200720262A (en) | Novel compounds ii | |
JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
MX2023012901A (es) | Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso. |